CN114450278A - 一个烟醇醚衍生物的马来酸盐及其晶型和应用 - Google Patents

一个烟醇醚衍生物的马来酸盐及其晶型和应用 Download PDF

Info

Publication number
CN114450278A
CN114450278A CN202080063645.3A CN202080063645A CN114450278A CN 114450278 A CN114450278 A CN 114450278A CN 202080063645 A CN202080063645 A CN 202080063645A CN 114450278 A CN114450278 A CN 114450278A
Authority
CN
China
Prior art keywords
chlorobenzyl
pyridine
bromo
phenylbenzyloxy
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080063645.3A
Other languages
English (en)
Other versions
CN114450278B (zh
Inventor
冯志强
陈晓光
马辰
杨阳
来芳芳
王雨辰
季鸣
郭凯静
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Materia Medica of CAMS
Tianjin Chase Sun Pharmaceutical Co Ltd
Original Assignee
Institute of Materia Medica of CAMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Materia Medica of CAMS filed Critical Institute of Materia Medica of CAMS
Publication of CN114450278A publication Critical patent/CN114450278A/zh
Application granted granted Critical
Publication of CN114450278B publication Critical patent/CN114450278B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

本发明涉及医药技术领域，公开了一个烟醇醚衍生物的马来酸盐及其晶型和应用，即(S)‑N‑(2‑(吡啶‑3‑甲氧基)‑4‑(2‑溴‑3‑苯基苄氧基)‑5‑氯苄基)丝氨酸异丙酯马来酸盐及其立体异构体、晶型及其制法和药物组合物与用途。具体而言，涉及式I所示的S)‑N‑(2‑(吡啶‑3‑甲氧基)‑4‑(2‑溴‑3‑苯基苄氧基)‑5‑氯苄基)丝氨酸异丙酯马来酸盐以及其晶型，其立体异构体及其制备方法，含有该化合物或其晶型的组合物，和该化合物或其晶型在制备治疗与PD‑1/PD‑L1信号通路有关的疾病如癌症、感染性疾病、自身免疫性疾病的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202080063645.3A 2019-09-09 2020-09-09 一个烟醇醚衍生物的马来酸盐及其晶型和应用 Active CN114450278B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910864721X 2019-09-09
CN201910864721 2019-09-09
PCT/CN2020/114137 WO2021047528A1 (zh) 2019-09-09 2020-09-09 一个烟醇醚衍生物的马来酸盐及其晶型和应用

Publications (2)

Publication Number Publication Date
CN114450278A true CN114450278A (zh) 2022-05-06
CN114450278B CN114450278B (zh) 2024-05-28

Family

ID=73309271

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010941188.5A Active CN111925318B (zh) 2019-09-09 2020-09-09 一个烟醇醚衍生物的马来酸盐及其晶型和应用
CN202080063645.3A Active CN114450278B (zh) 2019-09-09 2020-09-09 一个烟醇醚衍生物的马来酸盐及其晶型和应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010941188.5A Active CN111925318B (zh) 2019-09-09 2020-09-09 一个烟醇醚衍生物的马来酸盐及其晶型和应用

Country Status (5)

Country Link
EP (1) EP4029863A4 (zh)
JP (1) JP2022547208A (zh)
KR (1) KR20220061184A (zh)
CN (2) CN111925318B (zh)
WO (1) WO2021047528A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220061184A (ko) * 2019-09-09 2022-05-12 인스티튜드 오브 머테리아 메디카, 차이니스 아케데미 오브 메디컬 싸이언시스 니코티닐 알코올 에테르 유도체의 말레에이트, 이의 결정형, 및 이의 응용
WO2023050104A1 (zh) * 2021-09-28 2023-04-06 中国医学科学院药物研究所 二氢吲哚衍生物、及其制法和药物组合物与用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109153670A (zh) * 2016-05-23 2019-01-04 中国医学科学院药物研究所 烟醇醚类衍生物、及其制法和药物组合物与用途
CN111925318B (zh) * 2019-09-09 2023-02-28 天津红日药业股份有限公司 一个烟醇醚衍生物的马来酸盐及其晶型和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126428A1 (en) * 2012-02-21 2013-08-29 Allergan, Inc. Phenoxy derivatives as sphingosine 1-phosphate (s1p) receptor modulators
CN103787902B (zh) * 2014-02-17 2016-08-17 华东理工大学 苄基取代的苯胺类化合物及其应用
US9850225B2 (en) * 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109153670A (zh) * 2016-05-23 2019-01-04 中国医学科学院药物研究所 烟醇醚类衍生物、及其制法和药物组合物与用途
CN111925318B (zh) * 2019-09-09 2023-02-28 天津红日药业股份有限公司 一个烟醇醚衍生物的马来酸盐及其晶型和应用

Also Published As

Publication number Publication date
CN114450278B (zh) 2024-05-28
EP4029863A1 (en) 2022-07-20
WO2021047528A1 (zh) 2021-03-18
KR20220061184A (ko) 2022-05-12
CN111925318A (zh) 2020-11-13
JP2022547208A (ja) 2022-11-10
CN111925318B (zh) 2023-02-28
EP4029863A4 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
CN110054624B (zh) 盐酸小檗碱与咖啡酸共晶物及制备方法和其组合物与用途
CN111925318B (zh) 一个烟醇醚衍生物的马来酸盐及其晶型和应用
UA121482C2 (uk) Комбінація інгібітору протеасом, яким є бортезоміб, та інгібітору c-met для лікування множинної мієломи
US20150072987A1 (en) Novel compounds and therapeutic use thereof for protein kinase inhibition
EP3617198B1 (en) Guanidine derivative
JPH05163148A (ja) 抗腫瘍剤
CN111943906B (zh) 脒类衍生物、及其制法和药物组合物与用途
EP3459933B1 (en) Solid forms of a pharmaceutically active compound
US11504379B2 (en) Amide compound, and Pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same
CN113214138A (zh) 苯丙酸类衍生物、及其制法和药物组合物与用途
KR20240012513A (ko) 세스퀴테르펜 유도체, 그의 약학적 조성물 및 그의 제조 방법과 용도
RU2816099C1 (ru) Малеат эфирного производного никотинилового спирта, его кристаллическая форма и его применение
CN114929682B (zh) 苯并硫代吡喃酮类化合物的盐及其制备方法和用途
CN113444078B (zh) 抗凋亡蛋白Bcl-2抑制剂及其制备方法和应用
CN113214207A (zh) 橙皮素与甜菜碱共晶物a及制备方法和其组合物与用途
CN113214209A (zh) 橙皮素与卡马西平共晶物及制备方法和其组合物与用途
CN103304556B (zh) 含有苯并吡喃的希夫碱类化合物、其制备方法和用途
CN113214206B (zh) 橙皮素与甜菜碱共晶物b及制备方法和其组合物与用途
WO2022253261A1 (zh) Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
CN108186630B (zh) 靛红类似物在制备抗肿瘤药物中的应用
CN110248931B (zh) 一种双加氧酶抑制剂的盐及其制备方法和用途
CN115073442A (zh) 含双硫键化合物、及其制法和药物组合物与用途
US20210332056A1 (en) Crystal of pyrazolo[3,4-d]pyrimidine
JP2799368B2 (ja) 抗原虫剤
CN117700419A (zh) 一氧化氮供体型咔唑衍生物及其在治疗肿瘤疾病中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20240423

Address after: 301700, No. 20 Quanfa Road, Wuqing Development Zone, Tianjin New Technology Industrial Park, Wuqing District, Tianjin City

Applicant after: TIANJIN CHASESUN PHARMACEUTICAL Co.,Ltd.

Country or region after: China

Applicant after: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES

Address before: 100050 No.1, xiannongtan street, Xicheng District, Beijing

Applicant before: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES

Country or region before: China

TA01 Transfer of patent application right
GR01 Patent grant